Toll-free: (800) 566-3462



Main Oakland Lab Medical Director: Brad Lewis, MD 3023 Summit Street, Oakland, CA 94609 New Orleans Lab (\*\*local samples can be sent directly)
Medical Director: Gloria Coker, MD
8721 Oak Street, New Orleans, LA 70118
Phone: (504) 866-7090 / Fax: (504) 866-7091

Coagulation, Pla	atelets, Rare Dise	ease & Genetics	Phone: (510) 839-5600 / Fax: (510) 8	339-6153 Phone: (504) 866-7090 / Fax	c: (504) 866-7091	
PATIENT HISTORY				SUBMITTING FACILITY		
Patient's Name: (Last, First, M.I.) *			Specimen Date and Time:*	Client Account #:	*- PEOURED	
				Facility Name and Address:*	*= (REQUIRED)	
	OOB:*	MRN:*	Ordering Provider: (Last, First)*			
M F						
Platelet Count_	(K/uL)	), aPTT (sec.), PT_	(sec.), INR	•		
Hematocrit		ding History(Y/N),				
☐ Patient is antico	agulated	Please specify:		Phone:*	Fax for results:*	
Patient is on antiplatelet medication dabigatran fondaparinux			UFH □ apixaban □ rivaroxaban x □ other			
			rilinta	□STAT □ASAP □INSU		
PANEL TES	TING			GENETIC PANEL T	TESTING (STAT <2 DAYS)	
			el (aPTT-LA, dRVVT, Anticardiolipin	and □ Alport Syndrome	Genetic Panel (3 genes)	
Beta-2 Glycoprotein I Antibodies- IgG, IgM, IgA) □ Do not reflex to LA Panel □ Heparin Antibody Panel (TAT <24 Hrs)				□ aHUS Genetic Panel (20 genes)		
•	•		Heparin-induced Platelet Activation	)   C3 Glomerulopat	hy Genetic Panel (6 genes)	
☐ Hypercoagulability / Thrombophilia Panel (STAT <24 Hrs)				☐ Dysfibrinogenemia Genetic Panel (FGA, FGB, FGG)		
(Please vis	sit our website fo	or complete testing algorithn	n)	•	Lymphohistiocytosis (HLH) Genetic Panel	
•	•	Screen (ACL, dRVVT, aPT	· · · · · · · · · · · · · · · · · · ·	el Hemonhilia-Com	plete™ Genetic Panel (F8, F9, VWF, inversio	
			dex, dRVVT, Thrombin Time and PT	/INK) · ·	unctional Defect Panel (31 genes)	
	•	Jp (most common te F Profile, Fibrinogen Activity,	, ,		hrombocytopenia Panel (26 genes)	
•		Evaluation Work-up	•		v Disease (PKD) Genetic Panel (2 genes)	
		or complete testing algorithm			•	
University of the complete testing algorithm)  □ TMA-Complete TMA-Complete (20 genes)  □ Thrombophilia Genetic Panel (11 genes)						
(Factor VII	I Activity,VWF:A	ntigen, VWF:RCo, aPTT and i	f indicated, VWF:Multimer)		Genetic Panel (VWF and GP1BA)	
				□ VVVD Complete	Genetic Faner (VWF and GFTBA)	
TEST LIST						
□ ACL (Anticardiolipin - IgG, IgM and IgA)				a method) (indicate type above)	□ Protein C Activity and/or □ Antigen	
			→ □ Hexagonal Phosph  → ➤ □ Hexagonal Phosph  → □ Hexagon	OIIPIO (STACLOT-LA)**	□ Protein S Activity	
☐ ADAMTS13 Panel (Activity, Inhibitor and Antibody)			dy) ☐ HOMOCysteine ☐ HPP/OI Genetic Pa	nel (Hypophoephotosia)	☐ Protein S Antigen [Free] and/or ☐ [Total] ☐ Prothrombin Fragment 1.2	
, 3			☐ Inhibitor to Factor(		□ Prothrombin Gene Mutation	
□ Antithrombin III Activity and/or □ Antigen			,		□ Prothrombin Time □ Reflex to work-up	
□ Apixaban (Eliquis) Level			$\square \text{ II (2)} \qquad \square \text{ V (5)}$	□ VII (7) □ X (10)	□ PSAntibody (phosphotidylserine; IgG, IgM	
□ Beta-2 Glycoprotein I Antibody				ibra-specific Nijmegen Bethesda) **		
□ Euglobulin Clot Lysis Time			☐ Mixing Study (aPTT)	- reflex to incubated mix	□ Rivaroxaban (Xarelto) Level	
□ Factor Activity (aPTT-based) □ test all factors			☐ Mixing Study (PT)		$\  \   \Box  dRVVT (\text{dilute Russell Viper Venom Time})$	
				d/or □ A1298C) Mutations	☐ Soluble Complement 5b-9 (sC5b-9)	
_ · · · · · · · · · · · · · · · · · · ·			□ aPTT □ Reflex to worl	•	□ Soluble IL-2 Receptor Alpha (plasma	
			□ aPTT-LA (Lupus Sens	ity and/or □ Autoantibody	□ Soluble IL-2 Receptor Alpha (serum)	
					☐ Thrombin Generation (profile w/ETP)	
				r □ PAI-1 Gene Sequence	☐ Thrombin Time - TCT (confirmed w/PS)	
			□ Platelet Antibody II		☐ Thrombin-Antithrombin(TAT) ☐ VWF Activity (Ristocetin cofactor)	
	, ,	and/or ☐ Gene Sequencii		on Study - Comprehensive**	□ VWF Activity (Ristocetin coractor)	
□ Fibrinogen Activity and/or □ Antigen			□ Platelet ATP / Gran	□ Platelet ATP / Granule Release Study^^ □ \/\/\/□		
□ Hemlibra-specific Factor VIII (8) Activity**				on - ASA (Asprin Sensitivity)**	□ VWE Multimer (WE:Multimer)	
☐ Heparin Antibody Confirmation (wp-HIPA)			☐ Platelet Aggregation	n - RIPA (Ristocetin-induced)**	□ wp-HIPA (washed-platelet Heparin-induced Platelet Activation Assay)	
☐ Henarin Antihody Reflex (FLISA reflex to wn-HIPA)**			□ Platelet Electron M	ICroscopy Study LTA and/or □Genotype Assay		
			- Flavix Selisitivity -	LTA aliu/oi 🗆 Genotype Assay	Misc	
ADDITIONA	LINEODM	ATION		MACHAON USE ONLY		

Patients with insurance coverage other than Medicare are considered out-of-network and will be billed for services not covered by their insurance provider. Medicare patients must sign an ABN, either located on the reverse side of this form or downloaded from the Machaon Diagnostics website. Patient insurance billing services are provided in accordance with the Machaon Insurance Billing Policy. HMO or medical group covered patients may need a prior authorization if they seek reimbursement.

Specimen type received: \_\_\_\_\_\_ Aliquots: \_\_\_\_\_\_

Specimen type received: \_\_\_\_\_ Aliquots: \_\_\_\_\_

Tech initials: \_\_\_\_\_ Specimen received stamp: \_\_\_\_\_